The vote was clean. Every proposal put to Tevogen Inc. (Nasdaq: TVGN) stockholders at the August 24, 2026 annual meeting passed. What complicates the read-through is the size of what they said yes to: 100,000,000 new shares added to the company's 2024 Omnibus Incentive Plan, against just 6,416,540 shares issued and outstanding as of the July 23 record date.
Proposal 3, the plan amendment, drew 5,322,668 votes in favor and 98,744 against, with 1,209 abstentions and 533,520 broker non-votes. The approval margin holds. The risk is that one hundred million newly authorized incentive shares, against a float of 6,416,540, represent a pool that, at any meaningful deployment rate, resets the equity picture for TVGN holders.
Stockholders also approved a charter amendment permitting action by written consent in lieu of a formal meeting. Tevogen filed the Certificate of Amendment with the Delaware Secretary of State on August 26, 2026, effective immediately. The governance read-through is speed: a board that can act through written consent moves faster than one that must convene a meeting. Paired with the expanded incentive pool, the two approvals give management a wider operational toolkit.
Director elections were routine by the numbers. Dr. Keow Lin Goh and Victor Sordillo were re-elected as Class II directors for three-year terms each. Goh drew 5,397,703 votes in favor against 22,265; Sordillo drew 5,395,249 against 24,751. KPMG LLP was ratified as independent auditor for the fiscal year ending December 31, 2026, on a 5,939,035-to-14,666 vote.
The counterargument is the participation data. Of the 5,956,141 shares represented at the meeting, more than 5.3 million voted for the plan amendment and only 98,744 voted against. That is not reluctant approval. Holders who showed up registered broad support for a share pool that dwarfs the current float.
On balance, the meeting resolved authorization. It did not resolve deployment. The line to watch is grant disclosures in subsequent filings from Tevogen, whose warrants trade on Nasdaq under TVGNW and are exercisable at $575 per share. That is where the 100 million share expansion either tells a compensation story or a dilution one.